Pyxis Oncology (PYXS) News Today $3.50 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 7 at 2:01 AM | americanbankingnews.comAnalysts Set Pyxis Oncology, Inc. (NASDAQ:PYXS) Price Target at $9.00September 4 at 1:46 AM | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of "Buy" from AnalystsPyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has earned an average rating of "Buy" from the eight analysts that are currently covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers thAugust 29, 2024 | globenewswire.comPyxis Oncology to Participate in Two Upcoming Investor ConferencesAugust 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)August 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Gryphon Digital Mining (GRYP) and Pyxis Oncology (PYXS)August 16, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Friday.August 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology Amid Strong Financials and Promising Clinical TrialsAugust 14, 2024 | globenewswire.comPyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024August 10, 2024 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Buy" by AnalystsShares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been given an average recommendation of "Buy" by the eight analysts that are presently covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating. The average twelve-month target price amonAugust 8, 2024 | msn.comPyxis Oncology draws Buy at Stifel on lead assetAugust 8, 2024 | msn.comStifel Initiates Coverage of Pyxis Oncology (PYXS) with Buy RecommendationAugust 8, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Earns Buy Rating from Analysts at Stifel NicolausStifel Nicolaus started coverage on shares of Pyxis Oncology in a research note on Thursday. They set a "buy" rating and a $10.00 price target for the company.July 29, 2024 | globenewswire.comPyxis Oncology to Participate in the BTIG Virtual Biotechnology ConferenceJuly 28, 2024 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest UpdatePyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) was the recipient of a large increase in short interest in July. As of July 15th, there was short interest totalling 3,520,000 shares, an increase of 52.4% from the June 30th total of 2,310,000 shares. Based on an average daily trading volume, of 578,900 shares, the short-interest ratio is currently 6.1 days. Approximately 7.4% of the shares of the company are sold short.July 16, 2024 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned an average rating of "Buy" from the seven ratings firms that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year target prJune 28, 2024 | globenewswire.comPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 21, 2024 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of "Buy" from BrokeragesShares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have earned an average recommendation of "Buy" from the seven brokerages that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price targetJune 10, 2024 | globenewswire.comPyxis Oncology Expands Board of Directors with Appointment of Michael A. MetzgerJune 9, 2024 | marketbeat.comVestal Point Capital LP Takes $792,000 Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)Vestal Point Capital LP bought a new position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 440,000 shares of the company's stock, valuedMay 30, 2024 | marketbeat.comDecheng Capital LLC Acquires New Shares in Pyxis Oncology, Inc. (NASDAQ:PYXS)Decheng Capital LLC acquired a new stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 326,810 shares of the company's stock, valued at approximately $588,000. Pyxis OMay 30, 2024 | globenewswire.comPyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceMay 27, 2024 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Buy" by BrokeragesShares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have received an average rating of "Buy" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year pricMay 17, 2024 | marketbeat.comQ2 2024 Earnings Estimate for Pyxis Oncology, Inc. (NASDAQ:PYXS) Issued By William BlairPyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Stock analysts at William Blair cut their Q2 2024 earnings per share estimates for Pyxis Oncology in a report released on Tuesday, May 14th. William Blair analyst A. Hsieh now forecasts that the company will post earnings of ($0.34) per share forMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology on Strong Financials and Promising Clinical ProgressMay 16, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Rating Reiterated by HC WainwrightHC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Thursday.May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology on Robust Clinical Pipeline and Solid FinancialsMay 15, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Beats Expectations By $0.19 EPSPyxis Oncology (NASDAQ:PYXS - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.19. The firm had revenue of $16.15 million during the quarter, compared to analysts' expectations of $4.25 million.May 14, 2024 | globenewswire.comPyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024May 13, 2024 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Sees Significant Decline in Short InterestPyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) saw a significant decrease in short interest in April. As of April 30th, there was short interest totalling 1,850,000 shares, a decrease of 16.3% from the April 15th total of 2,210,000 shares. Approximately 4.0% of the shares of the stock are sold short. Based on an average daily volume of 749,400 shares, the short-interest ratio is presently 2.5 days.May 9, 2024 | globenewswire.comPyxis Oncology to Present at the RBC Capital Markets Global Healthcare ConferenceApril 30, 2024 | marketbeat.comabrdn plc Makes New Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS)abrdn plc acquired a new stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 708,303 shares of the company's stock, valued at approximately $1,275,000. abrdn plc owned approximately 1.60%April 28, 2024 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Down 18.1% in AprilPyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) was the target of a large drop in short interest in April. As of April 15th, there was short interest totalling 2,210,000 shares, a drop of 18.1% from the March 31st total of 2,700,000 shares. Approximately 4.8% of the company's stock are short sold. Based on an average trading volume of 909,000 shares, the days-to-cover ratio is currently 2.4 days.April 14, 2024 | finance.yahoo.comPYXS Oct 2024 10.000 callApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology as PYX-201 Showcases Promising Preclinical Data and Broad Therapeutic PotentialApril 10, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Wednesday.April 3, 2024 | msn.comWhy Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionMarch 28, 2024 | globenewswire.comPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Spectral AI (MDAI) and Pyxis Oncology (PYXS)March 28, 2024 | seekingalpha.comPyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The WaitMarch 27, 2024 | investorplace.com3 Biotech Stocks to Buy on the Dip: March 2024March 27, 2024 | msn.comPyxis Oncology gets $8M payment for sale pf royalty rightsMarch 27, 2024 | globenewswire.comPyxis Oncology Obtains $8 Million Payment for the Sale of Royalty RightsMarch 25, 2024 | markets.businessinsider.comOptimistic Buy Rating for Pyxis Oncology’s PYX-201 Based on Strong Safety Profile and Promising Therapeutic PotentialMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology on Strong Clinical and Financial ProspectsMarch 22, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Receives "Outperform" Rating from Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and set a $7.00 target price on shares of Pyxis Oncology in a report on Friday.March 22, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Given New $7.00 Price Target at HC WainwrightHC Wainwright increased their price target on shares of Pyxis Oncology from $4.00 to $7.00 and gave the stock a "buy" rating in a research note on Friday.March 22, 2024 | markets.businessinsider.comBuy Rating Affirmed: Pyxis Oncology’s Financial Health and Promising Drug Candidate PYX-201 Bolster OptimismMarch 21, 2024 | marketwatch.comPyxis Oncology Shares Fall 10% After Apparent Delay in ResultsMarch 21, 2024 | investorplace.comPYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023March 21, 2024 | benzinga.comPyxis Oncology: Q4 Earnings Insights Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address “Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account. Learn these 4 simple steps and protect your savings before it’s too late. PYXS Media Mentions By Week PYXS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PYXS News Sentiment▼0.670.55▲Average Medical News Sentiment PYXS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PYXS Articles This Week▼21▲PYXS Articles Average Week Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MGNX News ADCT News STTK News RANI News ACET News PASG News CRIS News VINC News CRGX News CRON News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PYXS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.